Comparing human epidermal growth factor receptor 2 amplification and expression using immunohistochemistry and silver in situ hybridisation in gastric carcinoma and lymph node metastasis

Abstract

Detecting the amplification and expression of human epidermal growth factor receptor (HER2) is important for planning trastuzumab treatment for patients with gastric carcinoma. The present study aimed to analyse HER2 amplification and expression in primary gastric adenocarcinoma tumours and metastatic lymph nodes using microarray methods, and to assess the potential contribution of these methods to treatment planning. In total, 60 patients with lymph node metastasis were included in the present study. Microarray blocks were obtained from the tissue blocks of primary tumours and metastatic lymph nodes. HER2 expression and amplification were investigated using immunohistochemical and silver in situ hybridisation (SISH) methods, respectively. Following immunohistochemical evaluation of HER2 in primary tumours, the sensitivity and specificity of the microarray method relative to the single block method were 69 and 100%, respectively. For HER2 detection in microarray block sections from primary tumours, the sensitivity and specificity of the SISH method relative to immunohistochemistry were 56 and 100%, respectively. When using SISH in microarray blocked sections, there was a high degree of concordance (98% concordance rate) between HER2 amplification in the primary tumour and the metastatic lymph node. Furthermore, the sensitivity and specificity of metastatic lymph node results relative to those of the primary tumour were 100 and 98%, respectively. Overall, the single block method was more reliable compared with the microarray method for planning treatment. When microarray blocking was used, a large number of samples must be tested to ensure reliable results. The immunohistochemical method is recommended as the first step as SISH alone increases the risk of false-negative results. Assessing HER2 amplification for treatment planning would be beneficial for primary tumours, as well as metastatic lymph nodes.

The Expression of E-cadherin & HER2 in Gastric Carcinoma

“…Tubular adenocarcinoma (22 of the 50 cases), papillary adenocarcinoma (3 of the 50 cases), poorly cohesive carcinoma (2 of the 50 cases, including signet ring carcinoma), mucinous adenocarcinoma (3 of the 50 cases), mixed adenocarcinoma (2 of the 50 cases), and carcinoma with lymphoid stroma were used to describe these cases histologically (1 of the 50 cases). This was consistent with a study conducted by Gulten et al [15]. Around 47% of cases were tubular adenocarcinoma, 5% papillary adenocarcinoma, 35% poorly cohesive carcinoma, 10% mucinous adenocarcinoma, 3% mixed adenocarcinoma, and 4% undifferentiated cancer.…”

Comparison of human epidermal growth factor receptor 2 and cancer stem cell markers like CD44 and CD133 expressions with clinicopathological parameters in gastric cancer

“…In one study, the sensitivity and specificity of the SISH method were reported as 56% and 100%, respectively, and the false-negative rate was 44%, according to the IHC method. These findings indicate that false negativity is very high in the SISH method, which is consistent with the findings of our study [51]. Studies investigating the relationship between clinicopathological features and HER2 expression have reported a close relationship between HER2 overexpression and gender, tumor differentiation, tumor location, tumor invasion, TNM stage, lymph node metastasis, and Lauren classification [48,50,52,53].…”